Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Executive Summary
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline
You may also be interested in...
MedImmune Emerges As Potential Takeover Target With Vaccines, Synagis
MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover
MedImmune Emerges As Potential Takeover Target With Vaccines, Synagis
MedImmune's growing vaccine franchise and recently revised co-marketing arrangement for Synagis (palivizumab) may position the firm well for a takeover
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years